Physician profile
Rig Patel
NPI 1063498822
$94,195.09
in general payments reported to CMS, 2019-2025
27 companies · $62K in 2025
The $62K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $143 · 2021: $684 · 2022: $830 · 2023: $404 · 2024: $30K · 2025: $62K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $74K · Travel and Lodging: $15K · Food and Beverage: $3,626 · Education: $15.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $73,500.00 |
| Travel and Lodging | $14,955.35 |
| Food and Beverage | $3,625.73 |
| Education | $15.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $89,776.62 | 2023-2025 | Voquezna |
| Abbvie INC. | $1,319.79 | 2019-2025 | |
| Boston Scientific Corporation | $1,094.83 | 2021-2025 | General - Biliary Devices, Axios, General - Polypectomy |
| Omega Medical Imaging, LLC | $537.95 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $238.75 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $178.99 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $131.84 | 2024-2025 | Zenpep |
| Romark Laboratories, Lc | $127.60 | 2019-2020 | |
| Siemens Medical Solutions USA, INC. | $120.71 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $83.86 | 2022-2023 | Dupixent |
| Madrigal Pharmaceuticals | $70.58 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.59 | 2019-2023 | Trulance |
| Braintree Laboratories, INC. | $66.48 | 2019-2024 | Suflave, Sutab |
| Merck Sharp & Dohme LLC | $64.00 | 2019-2022 | |
| Covidien LP | $55.56 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $43.15 | 2022-2025 | Ibsrela |
| Celgene Corporation | $30.84 | 2022-2023 | Zeposia |
| Qol Medical, LLC | $27.22 | 2025 | Sucraid |
| Sandoz INC. | $23.71 | 2024 | Hyrimoz |
| Mauna Kea Technologies, INC. | $22.38 | 2022 | |
| Janssen Biotech, INC. | $19.18 | 2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.24 | 2024 | Cyltezo |
| Gilead Sciences, INC. | $16.51 | 2025 | |
| Alfasigma USA, INC. | $15.91 | 2020 | |
| Evoke Pharma, INC. | $14.55 | 2025 | |
| Intra-Sana Laboratories | $13.71 | 2022 | |
| Ferring Pharmaceuticals INC. | $12.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rig Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.